ACCPL Accretion Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
Accretion Pharmaceuticals delivered strong H1 FY26 results, with significant revenue and PAT growth driven by IPO-funded capacity expansion and strategic focus on CDMO and export markets. While EBITDA margins saw a temporary compression due to scaling costs, management is confident in recovery as the business matures. The company is aggressively pursuing product and plant registrations in new geographies to sustain future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 13 | 19 | 39 | 44 |
| EBITDA | 3 | 4 | 8 | 7 |
| Net profit | 1 | 2 | 4 | 5 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
